Zidoyudine-Induced Hepatotoxicity
Authors: Gary Dubin
Journal: Annals of Internal Medicine (1989)

Brief Reports1 January 1989Zidoyudine-Induced HepatotoxicityGary Dubin, MD, Michael N. Braffman, MDGary Dubin, MDSearch for more papers by this author, Michael N. Braffman, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-110-1-85 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptZidovudine (3′-azido-3′-deoxythymidine) has been shown to decrease the frequency of opportunistic infections, increase the number of CD4 cells, and decrease mortality in patients infected with the human immunodeficiency virus (HIV) over a 6-month study period (1). Adverse reactions to zidovudine are common and include bone marrow suppression, nausea, insomnia, myalgia, and reduction of vitamin B12(2). The need to discontinue the drug for reasons other than hematologic toxicity is uncommon. We report a patient who experienced acute cholestatic hepatitis on initial exposure to and rechallenge with zidovudine and, as a result, was unable to receive further therapy with the drug....References1. FischlRichmanGrieco MDM. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and the AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987;317:185-91. CrossrefMedlineGoogle Scholar2. RichmanFischlGrieco DMM. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987;317:192-7. CrossrefMedlineGoogle Scholar3. MelamedMullerGoldCampbellKleinbergArmstrong ARJSMD. Possible zidovudine-induced hepatotoxicity [Letter]. JAMA. 1987;258:2063. CrossrefMedlineGoogle Scholar4. SchneidermanArensonCelloMargarettenWeber DDJWT. Hepatic disease in patients with the acquired immune deficiency syndrome (AIDS). Hepatology. 1987;7:925-30. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: From Pennsylvania Hospital and the University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania. For current author addresses, see end of text. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byInvestigations on the Influence of Zidovudine in the Pharmacokinetics of Isoniazid and Its Hepatotoxic Metabolites in RatsDrugs and ToxinsEvaluation of ameliorative ability of Silibinin against zidovudine and isoniazid-induced hepatotoxicity and hyperlipidaemia in rats: Role of Silibinin in Phase I and II drug metabolismSilibinin mitigates zidovudine-induced hepatocellular degenerative changes, oxidative stress and hyperlipidaemia in ratsNew Organochalcogen Multitarget Drug: Synthesis and Antioxidant and Antitumoral Activities of Chalcogenozidovudine DerivativesHepatic injury due to drugs, herbal compounds, chemicals and toxinsNucleoside reverse transcriptase inhibitors (NRTIs)-induced expression profile of mitochondria-related genes in the mouse liverTreatment of HCV and HIV coinfectionAntiretroviral-associated liver injuryTratamiento de la hepatitis crónica C en pacientes coinfectados con VIHReciprocal Interaction of Human Immunodeficiency Virus and Hepatitis C Virus InfectionsThrombocytose et cholestase chez un nouveau-né traité par zidovudineAcute Hepatitis and Bleeding Possibly Induced by Zidovudine and Ritonavir in an Infant with HIV InfectionHepatitis C Virus Infection as an Opportunistic Disease in Persons Infected with Human Immunodeficiency VirusZidovudine (AZT) causes an oxidation of mitochondrial DNA in mouse liverZidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletionChemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism, and adverse reactionsClinical toxicity of antiretroviral nucleoside analogsHepatitis C virus infection in a male homosexual cohort: risk factor analysis.Antimicrobial DrugsHEPATOTOXICITY OF ANTIVIRAL AGENTSInhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicityAdverse drug reactions in HIV seropositive patientsHepatotoxityAids: Part IIZidovudine: Five Years LaterGavin X. McLeod, MD, Scott M. Hammer, MDSevere hepatotoxicity in a patient receiving both acetaminophen and zidovudineZidovudine-induced hepatitisPharmakokinetik von Zidovudin bei HIV-infizierten Hämophilen mit chronischer HepatitisAids acquired by drug consumption and other noncontagious risk factorsConcurrent zidovudine-induced myopathy and hepatoxicity in patients treated for human immunodeficiency virus (HIV) infectionPathology of Childhood AIDSZidovudineMiscellaneous antibacterial and antiviral drugsElevation of serum thyroxine-binding globulin (but not of cortisol-binding globulin and sex hormone-binding globulin) associated with the progression of human immunodeficiency virus infectionZidovudine treatment for anti-HIV positive haemophiliacsMassive Hepatic Enlargement with Fatty Change Associated with KetoconazoleNewer drugs in intensive careZidovudine Update: 1990Zidovudine in Asymptomatic Human Immunodeficiency Virus InfectionDrug-induced Liver DiseaseNew Triazole Antifungal Agents (Fluconazole and Itraconazole) in the Treatment of HIV–related Gastrointestinal Candidiasis 1 January 1989Volume 110, Issue 1Page: 85-86KeywordsAdverse reactionsDrug therapyHospital medicineInfectious diseasesInsomniaMortalityMyalgiaNauseaOpportunistic infectionsToxicity Issue Published: 1 January 1989 PDF downloadLoading ...